Last reviewed · How we verify
Mycophenolate Mofeti
Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing proliferation of T and B lymphocytes.
Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing proliferation of T and B lymphocytes. Used for Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients, Active lupus nephritis, Autoimmune conditions requiring immunosuppression.
At a glance
| Generic name | Mycophenolate Mofeti |
|---|---|
| Sponsor | National Cancer Institute (NCI) |
| Drug class | Inosine monophosphate dehydrogenase (IMPDH) inhibitor |
| Target | IMPDH type II |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Mycophenolate mofetil is a prodrug that is rapidly hydrolyzed to mycophenolic acid (MPA), which preferentially inhibits IMPDH type II, the predominant form in activated lymphocytes. This leads to depletion of guanosine nucleotides required for DNA synthesis, causing selective antiproliferative effects on T and B cells while sparing other cell types. It is used as an immunosuppressant to prevent organ rejection and treat autoimmune conditions.
Approved indications
- Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients
- Active lupus nephritis
- Autoimmune conditions requiring immunosuppression
Common side effects
- Gastrointestinal disturbances (diarrhea, nausea, vomiting, abdominal pain)
- Leukopenia
- Anemia
- Infection
- Headache
- Tremor
Key clinical trials
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (PHASE1, PHASE2)
- Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycophenolate Mofeti CI brief — competitive landscape report
- Mycophenolate Mofeti updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI